The securities of Imagion Biosystems Limited (‘IBX’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of IBX, pending the release of an announcement regarding a capital raising.
Read the Suspension from Official Quotation announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)